

Correction

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients**Nathalie Luurssen-Masurel¹, Elise Van Mulligen¹,
Angelique Elisabeth Adriana Maria Weel^{1,2,3}, Johanna Maria Wilhelmina Hazes¹
and Pascal Hendrik Pieter de Jong¹, the tREACH group investigators**

Rheumatology 2021;60:5765–5774. <https://doi.org/10.1093/rheumatology/keab251>

In the originally published article, the names of the authors were transposed. These should read “Nathalie Luurssen-Masurel, Elise van Mulligen, Angelique Elisabeth Adriana Maria Weel, Johanna Maria Wilhelmina Hazes, Pascal Hendrik Pieter de Jong” instead of: “Luurssen-Masurel Nathalie, Van Elise Mulligen, Weel Angelique Elisabeth Adriana Maria, Hazes Johanna Maria Wilhelmina, de Jong Pascal Hendrik Pieter”. These errors have now been corrected online.

¹Department of Rheumatology, Erasmus Medical Center,

²Department of Rheumatology, Maasstad Hospital and ³Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands

Correspondence to: Nathalie Luurssen-Masurel, Department of Rheumatology, University Medical Center, Erasmus MC, Rotterdam 3015 CN, The Netherlands. E-mail: n.luurssen-masurel@erasmusmc.nl